21,067 results match your criteria pancreatic ductal


Bioengineered 3D models of human pancreatic cancer recapitulate in vivo tumour biology.

Nat Commun 2021 Sep 24;12(1):5623. Epub 2021 Sep 24.

Barts Cancer Institute, Queen Mary University of London, London, UK.

Patient-derived in vivo models of human cancer have become a reality, yet their turnaround time is inadequate for clinical applications. Therefore, tailored ex vivo models that faithfully recapitulate in vivo tumour biology are urgently needed. These may especially benefit the management of pancreatic ductal adenocarcinoma (PDAC), where therapy failure has been ascribed to its high cancer stem cell (CSC) content and high density of stromal cells and extracellular matrix (ECM). Read More

View Article and Full-Text PDF
September 2021

Biliary peritonitis after endoscopic retrograde cholangiopancreatography.

J Visc Surg 2021 Sep 21. Epub 2021 Sep 21.

Department of digestive surgery, HIA Bégin, 69, avenue de Paris, 94160 Saint-Mandé, France; Val de Grâce School, 1, place Alphonse-Laveran, 75230 Paris cedex 05, France. Electronic address:

Occurrence of a perforation after endoscopic CPRE sphincterotomy is a complication previously reported in the literature, with frequent repercussions on the duodenum and the periampullary region (Stapfer types 1 and 2); treatment modalities are strictly codified. During an endoscopic procedure, it may be associated with manipulation of a guide wire, generally leading to isolated pneumoretroperitoneum (Stapfer type 4), which is conservatively treated. Secondarily to endoscopic maneuvers, Stapfer type 3 may also occur, causing pancreatic or biliary ductal lesions. Read More

View Article and Full-Text PDF
September 2021

A 584 bp deletion in CTRB2 inhibits chymotrypsin B2 activity and secretion and confers risk of pancreatic cancer.

Am J Hum Genet 2021 Sep 18. Epub 2021 Sep 18.

Laboratory of Translational Genomics, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD 20892, USA. Electronic address:

Genome-wide association studies (GWASs) have discovered 20 risk loci in the human genome where germline variants associate with risk of pancreatic ductal adenocarcinoma (PDAC) in populations of European ancestry. Here, we fine-mapped one such locus on chr16q23.1 (rs72802365, p = 2. Read More

View Article and Full-Text PDF
September 2021

Does drainage or resection predict subsequent interventions and long-term quality of life in patients with Grade IV pancreatic injuries: A population-based analysis.

J Trauma Acute Care Surg 2021 Oct;91(4):708-715

From the Department of Surgery (C.G.B., A.W.K.), University of Calgary, Calgary, Alberta, Canada; Department of Surgery (W.L.B.), Scripps Clinic Medical Group, La Jolla, California; Department of Surgery (S.M.H.), University of British Columbia, Vancouver, BC, Canada; Department of Surgery (K.V., N.G.P.), Western University, London, Ontario, Canada; and Department of Surgery (M.K.), Cook County Hospital, Chicago, Illinois.

Background: Clinical equipoise remains significant for the treatment of Grade IV pancreatic injuries in stable patients (i.e., drainage vs. Read More

View Article and Full-Text PDF
October 2021

The EUS molecular evaluation of pancreatic cancer: A prospective multicenter cohort trial.

Endosc Ultrasound 2021 Sep 23. Epub 2021 Sep 23.

Department of Surgery, School of Clinical Sciences at Monash Health, Monash University, Clayton, Victoria, Australia.

Background And Objectives: Patients with locally advanced or metastatic pancreatic ductal adenocarcinoma (A-PDAC) are not candidates for surgical resection and are often offered palliative chemotherapy. The ready availability of a safe and effective tumor sampling technique to provide material for both diagnosis and comprehensive genetic profiling is critical for informing precision medicine in A-PDAC, thus potentially increasing survival. The aim of this study is to examine the feasibility and benefits of routine comprehensive genomic profiling (CGP) of A-PDAC using EUS-FNA material. Read More

View Article and Full-Text PDF
September 2021

Can a simplified CT response criteria for vascular involvement in pancreatic adenocarcinoma after neoadjuvant therapy predict survival in patients who achieved subsequent R0 resection?

Abdom Radiol (NY) 2021 Sep 23. Epub 2021 Sep 23.

Department of Radiology and Biomedical Imaging, Yale School of Medicine, New Haven, CT, USA.

Purpose: To investigate if a simplified image based scoring system assessing treatment response after neoadjuvant therapy (NAT) can predict survival in patients with pancreatic ductal adenocarcinoma (PDAC) who achieved subsequent R0 resection.

Methods: Retrospective analysis of 57 PDAC patients (male = 29, 51%) with mean age of 64 at diagnosis (range 42-79) who received NAT and R0 resection. Post-NAT overall, arterial and venous imaging response was characterized as improved, similar, or worse by 2 readers independently followed by consensus review. Read More

View Article and Full-Text PDF
September 2021

Identification of Novel Molecular Therapeutic Targets and Their Potential Prognostic Biomarkers Among Kinesin Superfamily of Proteins in Pancreatic Ductal Adenocarcinoma.

Front Oncol 2021 7;11:708900. Epub 2021 Sep 7.

Department of Abdominal Oncology, West China Hospital of Sichuan University, Chengdu, China.

Background: Kinesin superfamily of proteins (KIFs) has been broadly reported to play an indispensable role in the biological process. Recently, emerging evidence reveals its oncogenic role in various cancers. However, the prognostic, oncological, and immunological values of KIFs have not been comprehensively explored in pancreatic ductal adenocarcinoma (PDAC) patients. Read More

View Article and Full-Text PDF
September 2021

Extracellular vesicles from pancreatic ductal adenocarcinoma EUS-FNA samples contain a protein barcode.

J Hepatobiliary Pancreat Sci 2021 Sep 23. Epub 2021 Sep 23.

Department of Gastroenterology and Hepatology, Graduate School of Medicine, Mie University, 2-174 Edobashi, Tsu, 514-8507, Japan.

Background: The survival rate of pancreatic ductal adenocarcinoma (PDAC) is very poor because early detection is difficult. Extracellular vesicles (EVs) are released from cells associating with the cellular condition and circulated in the blood. We aimed to identify EV proteins from endoscopic ultrasound-fine needle aspiration (EUS-FNA) biopsy samples in order to develop novel biomarkers for PDAC. Read More

View Article and Full-Text PDF
September 2021

Ferroptosis-related lncRNA pairs to predict the clinical outcome and molecular characteristics of pancreatic ductal adenocarcinoma.

Brief Bioinform 2021 Sep 22. Epub 2021 Sep 22.

Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.

Ferroptosis is a form of regulated cell death initiated by oxidative perturbations that can be blocked by iron chelators and lipophilic antioxidants, and ferroptosis may be the silver bullet treatment for multiple cancers, including immunotherapy- and chemotherapy-insensitive cancers such as pancreatic ductal adenocarcinoma (PDAC). Numerous studies have noted that long non-coding RNAs (lncRNAs) regulate the biological behaviour of cancer cells by binding to DNA, RNA and protein. However, few studies have reported the role of lncRNAs in ferroptosis processes and the function of ferroptosis-associated lncRNAs. Read More

View Article and Full-Text PDF
September 2021

Solid pseudopapillary neoplasm of the pancreas.

Authors:
Ayo O Omiyale

World J Hepatol 2021 Aug;13(8):896-903

Department of Cellular Pathology, Imperial College Healthcare NHS Trust, Charing Cross Hospital, London W6 8RF, United Kingdom.

Solid pseudopapillary neoplasms are rare. This article reviews the clinical and pathologic features of solid pseudopapillary neoplasm of the pancreas, including the epidemiology, cytology, molecular pathology, differential diagnosis, treatment, and prognosis. Solid pseudopapillary neoplasms are low-grade malignant tumours of the pancreas characterized by poorly cohesive epithelial cells with solid and pseudopapillary patterns. Read More

View Article and Full-Text PDF

Updates on adjuvant and neoadjuvant treatment strategies for surgically resectable and borderline resectable pancreatic ductal adenocarcinoma.

Ther Adv Med Oncol 2021 18;13:17588359211045861. Epub 2021 Sep 18.

Division of Oncology, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.

Pancreatic cancer is the third leading cause of cancer-related mortality in the US. Outcomes for patients with pancreatic cancer are poor as curative approaches are only available to the minority of patients who have localized tumors for which surgery may be an option. The past decade has established fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) as the new standard of care following resection for fit patients with resectable pancreatic tumors. Read More

View Article and Full-Text PDF
September 2021

Nanomedicine Strategies to Enhance Tumor Drug Penetration in Pancreatic Cancer.

Authors:
Tao Lu Jai Prakash

Int J Nanomedicine 2021 15;16:6313-6328. Epub 2021 Sep 15.

Engineered Therapeutics Group, Department of Biomaterials Science and Technology, University of Twente, Enschede, The Netherlands.

Pancreatic cancer is one of the most malignant tumors with one of the worst survival rates due to its insidious onset and resistance to therapies. Most therapeutics show a desired anticancer effect in vitro; however, very poor efficacy in vivo because of the limited drug delivery and penetration into pancreatic tumors attributed to the abundance of the tumor stroma, ie, the fibrotic tumor microenvironment surrounding the cancer cells. For a better understanding of the challenges posed by the pancreatic tumor stroma, we outline the key features of the tumor microenvironment. Read More

View Article and Full-Text PDF
September 2021

Targeting the IGF-axis potentiates immunotherapy for pancreatic ductal adenocarcinoma liver metastases by altering the immunosuppressive microenvironment.

Mol Cancer Ther 2021 Sep 22. Epub 2021 Sep 22.

Department of Surgery, Medicine and Oncology, McGill University Health Centre

Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignancy, resistant to chemotherapy and associated with high incidence of liver metastases and poor prognosis. Using murine models of aggressive PDAC, we show here that in mice bearing hepatic metastases, treatment with the IGF-Trap, an inhibitor of type 1 insulin like growth factor receptor (IGF-IR) signaling, profoundly altered the local, immunosuppressive tumor microenvironment in the liver, curtailing the recruitment of myeloid derived suppressor cells, reversing innate immune cell polarization and inhibiting metastatic expansion. Significantly, we found that immunotherapy with anti PD-1 antibodies also reduced the growth of experimental PDAC liver metastases, and this effect was enhanced when combined with IGF-Trap treatment, resulting in further potentiation of a T cell response. Read More

View Article and Full-Text PDF
September 2021

MYC levels regulate metastatic heterogeneity in pancreatic adenocarcinoma.

Cancer Discov 2021 Sep 22. Epub 2021 Sep 22.

Ontario Institute for Cancer Research.

The degree of metastatic disease varies widely amongst cancer patients and impacts clinical outcomes. However, the biological and functional differences that drive the extent of metastasis are poorly understood. We analyzed primary tumors and paired metastases using a multi-fluorescent lineage-labeled mouse model of pancreatic ductal adenocarcinoma (PDAC) - a tumor type where most patients present with metastases. Read More

View Article and Full-Text PDF
September 2021

Mesenchymal Lineage Heterogeneity Underlies Non-Redundant Functions of Pancreatic Cancer-Associated Fibroblasts.

Cancer Discov 2021 Sep 21. Epub 2021 Sep 21.

Cell, Developmental & Cancer Biology, Oregon Health & Science University School of Medicine

Cancer-associated fibroblast (CAF) heterogeneity is increasingly appreciated, but the origins and functions of distinct CAF subtypes remain poorly understood. The abundant and transcriptionally diverse CAF population in pancreatic ductal adenocarcinoma (PDAC) is thought to arise from a common cell of origin, pancreatic stellate cells (PSCs), with diversification resulting from cytokine and growth factor gradients within the tumor microenvironment. Here we analyzed the differentiation and function of PSCs during tumor progression in vivo. Read More

View Article and Full-Text PDF
September 2021

MUC5AC Expression in Various Tumor Types and Nonneoplastic Tissue: A Tissue Microarray Study on 10 399 Tissue Samples.

Technol Cancer Res Treat 2021 Jan-Dec;20:15330338211043328

Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Mucin 5AC (MUC5AC) belongs to the glycoprotein family of secreted gel-forming mucins and is physiologically expressed in some epithelial cells. Studies have shown that MUC5AC is also expressed in several cancer types suggesting a potential utility for the distinction of tumor types and subtypes. To systematically determine MUC5AC expression in normal and cancerous tissues, a tissue microarray containing 10 399 samples from 111 different tumor types and subtypes as well as 608 samples of 76 different normal tissue types was analyzed by immunohistochemistry. Read More

View Article and Full-Text PDF
September 2021

miR-802 Suppress Acinar-to-Ductal Reprogramming during Early Pancreatitis and Pancreatic Carcinogenesis.

Gastroenterology 2021 Sep 18. Epub 2021 Sep 18.

Institute of Molecular Health Sciences, ETH Zürich, Otto-Stern-Weg 7, 8093 Zürich, Switzerland; Medical Faculty, University of Zürich, 8091 Zürich, Switzerland. Electronic address:

Background & Aims: Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive tumor that is almost uniformly lethal in humans. Activating mutations of KRAS are found in >90% of human PDACs and are sufficient to promote acinar-to-ductal metaplasia (ADM) during tumor initiation. The roles of miRNAs in oncogenic Kras-induced ADM are incompletely understood. Read More

View Article and Full-Text PDF
September 2021

Pancreatic Cancer: A Review.

JAMA 2021 09;326(9):851-862

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.

Importance: Pancreatic ductal adenocarcinoma (PDAC) is a relatively uncommon cancer, with approximately 60 430 new diagnoses expected in 2021 in the US. The incidence of PDAC is increasing by 0.5% to 1. Read More

View Article and Full-Text PDF
September 2021

Prospective trial to evaluate the prognostic value of different nutritional assessment scores for survival in pancreatic ductal adenocarcinoma (NURIMAS Pancreas SURVIVAL).

J Cachexia Sarcopenia Muscle 2021 Sep 20. Epub 2021 Sep 20.

Department of General, Visceral and Transplantation Surgery, University of Heidelberg, Heidelberg, Germany.

Background: Malnutrition is associated with poor survival in pancreatic cancer patients. Nutritional scores show great heterogeneity diagnosing malnutrition. The aim of this study was to find the score best suitable to identify patients with malnutrition related to worse survival after surgery for pancreatic ductal adenocarcinoma (PDAC). Read More

View Article and Full-Text PDF
September 2021

Identifying symptoms associated with diagnosis of pancreatic exocrine and neuroendocrine neoplasms: a nested case-control study of the UK primary care population.

Br J Gen Pract 2021 Jul 12. Epub 2021 Jul 12.

Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford.

Background: Pancreatic cancer has the worst survival rate among all cancers. Almost 70% of patients in the UK were diagnosed at Stage IV.

Aim: This study aimed to investigate the symptoms associated with the diagnoses of pancreatic ductal adenocarcinoma (PDAC) and pancreatic neuroendocrine neoplasms (PNEN), and comparatively characterise the symptomatology between the two tumour types to inform earlier diagnosis. Read More

View Article and Full-Text PDF

Exosomes secreted from human umbilical cord mesenchymal stem cells promote pancreatic ductal adenocarcinoma growth by transferring miR-100-5p.

Tissue Cell 2021 Aug 14;73:101623. Epub 2021 Aug 14.

Department of General Surgery, Xuanwu Hospital, Capital Medical University, Beijing, 100053, China; Clinical Center for Acute Pancreatitis, Capital Medical University, Beijing, 100053, China. Electronic address:

Purpose: Although human umbilical cord mesenchymal stem cells (hucMSCs) can contribute to the growth of tumors, including pancreatic ductal adenocarcinoma (PDAC), however, little is known about the exact mechanisms by which the exosomes secreted from hucMSCs (hucMSCs-exo) have an oncogenic effect on the physiopathology of PDAC. The effects of hucMSCs on tumor development are attributed to hucMSCs-exo, which deliver unique proteins and miRNAs to cancer cells.

Methods: HucMSCs and exosomes were isolated and confirmed via transmission electron microscopy, nanoparticle tracking analysis and western blot. Read More

View Article and Full-Text PDF

Novel murine pancreatic tumor model demonstrates immunotherapeutic control of tumor progression by a protein.

Infect Immun 2021 Sep 20:IAI0050821. Epub 2021 Sep 20.

Department of Medical Microbiology and Immunology, University of Wisconsin - Madison, 1550 Linden Drive, Madison, WI 53706.

Pancreatic ductal adenocarcinoma is the fourth leading cause of cancer related death in the United States with few effective treatments available and only 10% of those diagnosed surviving 5 years. Although immunotherapeutics are a growing field of study in cancer biology, there has been little progress in their use for the treatment of pancreatic cancer. Pancreatic cancer is considered a nonimmunogenic tumor because the tumor microenvironment does not easily allow for the immune system, even when stimulated, to attack the cancer. Read More

View Article and Full-Text PDF
September 2021

Systematic review and trial sequential analysis of high-intensity focused ultrasound combined with chemotherapy versus chemotherapy in the treatment of unresectable pancreatic ductal adenocarcinoma.

Int J Hyperthermia 2021 ;38(1):1375-1383

State Key Laboratory of Ultrasound in Medicine and Engineering, College of Biomedical Engineering, Chongqing Medical University, Chongqing, China.

Purpose: This study aimed to compare the survival benefits between high-intensity focused ultrasound (HIFU) combined with chemotherapy and chemotherapy alone in patients with unresectable pancreatic ductal adenocarcinoma (PDAC).

Methods: All randomized clinical trials (RCTs) and observational studies were systematically searched through the databases of PubMed, EMBASE, CNKi and CQVIP up to December 2020. Case reports, case series and nonsystematic reviews were excluded. Read More

View Article and Full-Text PDF
January 2021

Engineering of biomaterials for tumor modeling.

Mater Today Adv 2020 Dec 12;8. Epub 2020 Nov 12.

School of Mechanical Engineering, Purdue University, West Lafayette, IN, USA.

Development of biomaterials mimicking tumor and its microenvironment has recently emerged for the use of drug discovery, precision medicine, and cancer biology. These biomimetic models have developed by reconstituting tumor and stroma cells within the 3D extracellular matrix. The models are recently extended to recapitulate the tumor microenvironment, including biological, chemical, and mechanical conditions tailored for specific cancer type and its microenvironment. Read More

View Article and Full-Text PDF
December 2020

Activated Pancreatic Stellate Cells Enhance the Warburg Effect to Cause the Malignant Development in Chronic Pancreatitis.

Front Oncol 2021 3;11:714598. Epub 2021 Sep 3.

Department of General Surgery, The First Affiliated Hospital of University of Science & Technology of China, Anhui Provincial Hospital, Hefei, China.

Chronic pancreatitis (CP) is a precancerous condition associated with pancreatic ductal adenocarcinoma (PDAC), but its evolutionary mechanism is unclear. Pancreatic stellate cells (PSCs) are closely related to the occurrence and development of CP and PDAC, but it is not clear whether PSCs play a key role in this "inflammation-cancer transition". Our research found that co-culture with activated PSCs promoted the proliferation, migration and invasion of normal pancreatic duct epithelial cells and pancreatic cancer cells. Read More

View Article and Full-Text PDF
September 2021

Infection Masquerading as Recurrence of Pancreatic Ductal Adenocarcinoma: A Cautionary Tale.

Cureus 2021 Aug 8;13(8):e17010. Epub 2021 Aug 8.

Internal Medicine Residency Program, Baton Rouge General Medical Center, Baton Rouge, USA.

We present a case of a 59-year-old male undergoing adjuvant chemotherapy for his pancreatic adenocarcinoma post-surgical resection. He had an acute rise in carbohydrate antigen (CA) 19-9 level, which raised suspicion of metastatic disease. Instead, the patient was diagnosed to have a liver abscess, the treatment of which brought the CA 19-9 level back to normal. Read More

View Article and Full-Text PDF

A radiomics model that predicts lymph node status in pancreatic cancer to guide clinical decision making: A retrospective study.

J Cancer 2021 22;12(20):6050-6057. Epub 2021 Aug 22.

Department of Hepatobiliary and Pancreatic Surgery, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310009, China.

To construct a radiomics-based model for predicting lymph node (LN) metastasis status in pancreatic ductal adenocarcinoma (PDAC) before therapy and to evaluate its prognostic clinical value. We retrospectively collected preoperative CT scans of 130 PDAC patients who underwent original tumor resection and LN dissection in the entire cohort between January 2014 and December 2017. Radiomics features were systematically extracted and analyzed from CT scans of 89 patients in the primary cohort. Read More

View Article and Full-Text PDF

Diverse and precision therapies open new horizons for patients with advanced pancreatic ductal adenocarcinoma.

Hepatobiliary Pancreat Dis Int 2021 Sep 8. Epub 2021 Sep 8.

Cancer Center, the First Hospital of Jilin University, Changchun 130021, China. Electronic address:

Pancreatic ductal adenocarcinoma (PDAC) is a common cause of cancer-related death, and most patients are with advanced disease when diagnosed. At present, despite a variety of treatments have been developed for PDAC, few effective treatment options are available; on the other hand, PDAC shows significant resistance to chemoradiotherapy, targeted therapy, and immunotherapy due to its heterogeneous genetic profile, molecular signaling pathways, and complex tumor immune microenvironment. Nevertheless, over the past decades, there have been many new advances in the key theory and understanding of the intrinsic mechanisms and complexity of molecular biology and molecular immunology in pancreatic cancer, based on which more and more diverse new means and reasonable combination strategies for PDAC treatment have been developed and preliminary breakthroughs have been made. Read More

View Article and Full-Text PDF
September 2021

Laparoscopic distal pancreatectomy for intraductal papillary mucinous neoplasm-associated pancreatic cancer: A case report.

Int J Surg Case Rep 2021 Sep 10;87:106376. Epub 2021 Sep 10.

Department of Surgery, Fukuoka University Chikushi Hospital, 1-1-1 Zokumyoin, Chikushinoshi, Fukuoka 818-8502, Japan. Electronic address:

Introduction And Importance: Intraductal papillary mucinous neoplasm (IPMN) of the pancreas is often found incidentally during examination for other diseases. In addition to the risk of malignant transformation, patients with IPMN are at risk of developing pancreatic cancer. We report a case of pancreatic tail cancer that developed separately from a preexisting IPMN after minimally invasive esophagectomy for cancer of the esophagogastric junction and was resected successfully by laparoscopic distal pancreatectomy. Read More

View Article and Full-Text PDF
September 2021

Interplay of Tumor Microenvironment Factors and Cancer Stem Cell Enrichment in Pancreatic Ductal Adenocarcinoma.

Gastroenterology 2021 Sep 15. Epub 2021 Sep 15.

Department of Medicine, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma. Electronic address:

View Article and Full-Text PDF
September 2021